Show simple item record

dc.contributor.authorHamilton-Craig, I
dc.contributor.authorKostner, K
dc.contributor.authorColquhoun, D
dc.contributor.authorWoodhouse, S
dc.contributor.editorRoland Asmar
dc.date.accessioned2017-05-03T15:15:57Z
dc.date.available2017-05-03T15:15:57Z
dc.date.issued2010
dc.date.modified2011-03-09T07:32:22Z
dc.identifier.issn1176-6344
dc.identifier.doi10.2147/VHRM.S13496
dc.identifier.urihttp://hdl.handle.net/10072/35734
dc.description.abstractHigh-dose potent statin therapy in combination with ezetimibe is now standard practice for the treatment of adult patients with heterozygous familial hypercholesterolemia (heFH), as the result of numerous studies in patients with primary hypercholesterolemia or heFH. These studies have shown the combination to be both effective and safe in the short to medium term. Recently, short-term ezetimibe therapy has also been shown to be effective and safe in combination with statin therapy for children and adolescents with heFH. Effective statin-ezetimibe combination therapy is capable of achieving near-normal lipid profiles in heFH patients, with expected improvement in risk for cardiovascular disease (CVD) and improved life expectancy resulting predominantly from reduction in levels of low-density lipoprotein cholesterol. There are few data to support a pleiotropic action of ezetimibe with regard to CVD benefit, unlike therapy with statins. No serious and unexpected clinical adverse effects of combination statin-ezetimibe therapy have emerged till date, although data are limited in children and adolescents, for whom longer-term studies are required. Recent data suggesting possible proatherogenic effects of ezetimibe require confirmation. One large long-term randomized controlled clinical outcomes trial is in progress in non-FH patients to determine the efficacy and safety of ezetimibe therapy; it is unlikely that such a trial will ever be performed in patients with FH.
dc.description.peerreviewedYes
dc.description.publicationstatusYes
dc.format.extent305630 bytes
dc.format.mimetypeapplication/pdf
dc.languageEnglish
dc.language.isoeng
dc.publisherDove Press
dc.publisher.placeUnited Kingdom
dc.relation.ispartofstudentpublicationN
dc.relation.ispartofpagefrom1023
dc.relation.ispartofpageto1037
dc.relation.ispartofjournalVascular Health and Risk Management
dc.relation.ispartofvolume6
dc.rights.retentionY
dc.subject.fieldofresearchCardiology (incl. cardiovascular diseases)
dc.subject.fieldofresearchClinical sciences
dc.subject.fieldofresearchcode320101
dc.subject.fieldofresearchcode3202
dc.titleCombination therapy of statin and ezetimibe for the treatment of familial hypercholesterolemia
dc.typeJournal article
dc.type.descriptionC1 - Articles
dc.type.codeC - Journal Articles
gro.facultyGriffith Health, School of Medicine
gro.rights.copyright© 2010 Hamilton-Craig et al, publisher and licencee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited. Please refer to the journal's website for access to the definitive, published version.
gro.date.issued2010
gro.hasfulltextFull Text
gro.griffith.authorHamilton-Craig, Ian


Files in this item

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record